Abstract
The pathogenesis of thyroid ophthalmopathy and its relation to thyroid gland dysfunction defies elucidation, and thus only palliative therapy exists. If and how antithyroid therapy affects the course of thyroid eye disease remains controversial. Research continues to try to reveal a subset of patients who respond best to corticosteroid or radiation treatment. Innovations in the surgical correction of upper eyelid retraction, orbital decompression technique, and the approach to restrictive myopathy help improve outcome. Preliminary knowledge concerning octreotide suggests that it may play a role in thyroid ophthalmopathy treatment and prevention. Future studies still need to answer basic questions about the treatment of thyroid ophthalmopathy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
